OCT 26, 2015 8:02 AM PDT

New Immunosuppressant Drug For Autoimmune Blood Diseases Undergoing Clinical Trials

WRITTEN BY: Kara Marker
Sirolimus, an immunosuppressant drug, as recently been used in clinical trials for patients with autoimmune blood disorders. Patients benefitting from sirolumus are highly resistant or intolerant to normal corticosteroid immunosuppressive therapy. Autoimmune lymphoproliferative syndrome (ALPS) is particularly responsive to experimental sirolimus treatments. This disease is extremely rare; only 200 ALPS patients have been identified worldwide (NIH). 

ALPS is a genetic disease that inhibits the body from producing the healthy amount of lymphoctes, resulting in a chronically swollen liver, spleen, and lymph nodes (NIH). ALPS and other autoimmune blood disorders can cause anemia, uncontrolled bleeding, and infection as the immune system targets healthy hematocytes (blood cells). 
A PET scan of an ALPS patient
Corticosteroids were discovered in the 1940s and are used often for regulating inflammation in autoimmune diseases. Unfortunately, their anti-inflammatory abilities are not without long-term adverse side effects. A 2011 review in Molecular and Cellular Endocrinology described corticosteroid treatment "clinical efficacy" as "compromised by the metabolic effects of long-treatment," including osteoporosis, hypertension, and type 2 diabetes. 

To bypass these unfavorable side effects as well as provide an option for ALPS patients resistant/intolerant to corticosteroids, scientists from the Children's Hospital of Philadelphia ran a clinical trial of 30 patients between 5 and 19 years old to see how sirolimus could be used to treat ALPS. 

Sirolimus has traditionally been prescribed to prevent the rejection of kidney transplants by suppressing the immune system (MedlinePlus). ALPS patients in the clinical trial received six months of sirolimus treatment, and there was large success with participants reaching normal blood cell counts. Patients also received a check-up after two years, and there were very few recorded adverse side effects. In addition, these patients were able to stop all other steroid treatments and rely on sirolimus to keep their disease in check. 

Senior study author David Teachey, MD, looks to sirolimus as a way for young ALPS patients to achieve "an improved quality of life as they continue treatment into adulthood."

In 2012, the Children's Hospital Boston also did a sirolumus clinical trail. Riley Cerabona, a child with CLOVES syndrome, participated in the trial. CLOVES (Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevus, Scoliosis) is very rare (ClovesSyndrome.org). Watch the video below to hear her story and more about the potential of sirolimus as an immunosuppressant. 



Source: EurekAlert

 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
APR 21, 2021
Health & Medicine
Topical Probiotics Are a Beneficial Acne Treatment
APR 21, 2021
Topical Probiotics Are a Beneficial Acne Treatment
Research underway is showing topical probiotics to be a beneficial treatment for acne vulgaris. Topical probiotics are a ...
MAY 20, 2021
Immunology
Why Delaying the 2nd COVID Shot is Paying Off for Some
MAY 20, 2021
Why Delaying the 2nd COVID Shot is Paying Off for Some
A new study indicates that delaying the second “booster” dose of the Pfizer-BioNTech COVID vaccine (to 11-12 ...
MAY 19, 2021
Immunology
Intestinal Macrophages Promote Chronic Inflammation in Obesity
MAY 19, 2021
Intestinal Macrophages Promote Chronic Inflammation in Obesity
A research group from Switzerland hypothesized that immune cells in the gut (gastrointestinal tract) must trigger chroni ...
MAY 23, 2021
Health & Medicine
Paronychia: What Is It and How Do You Treat It?
MAY 23, 2021
Paronychia: What Is It and How Do You Treat It?
It's one of the most common infections of the hand that nail biters are all too familiar with. Better known as a han ...
MAY 31, 2021
Immunology
Engineering Faster, More Agile T Cell Cancer Fighters
MAY 31, 2021
Engineering Faster, More Agile T Cell Cancer Fighters
Cell therapies use engineered T cells extracted from the patient’s own immune system to rally an attack on tumors. ...
JUN 15, 2021
Health & Medicine
Enabling biomarker discovery with functional proteomics
JUN 15, 2021
Enabling biomarker discovery with functional proteomics
Clinical biomarkers are critical for the acceleration of curative medicines. The identification of these novel clinical ...
Loading Comments...